<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
NEW YORK–(BUSINESS WIRE)–Holocene Advisors, LP (“Holocene”), a fundamental investment management firm and significant shareholder of Acceleron Pharma Inc. (Nasdaq: XLRN) (“Acceleron” or the “Company”), today announced that it does not intend to tender its shares into Merck & Co.’s (NYSE: MRK) proposed $180 per share offer for the Company announced on September 30, 2021. Holocene stated the following: “As a large shareholder in Acceleron, we believe the Company’s management team has done a
...read full article on Business Wire
